Anticoagulant / infark

PKC activators and anticoagulant in regimen for treating stroke

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

The present disclosure relates generally to administration of an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administering at least one PKC activator for a duration of treatment to treat a subject following ischemic stroke.

PKC activators and anticoagulant in regimen for treating stroke

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

The present disclosure relates generally to administration of an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administering at least one PKC activator for a duration of treatment to treat a subject following ischemic stroke.

Oral anticoagulant/platelet inhibitor low dose formulation

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION 1. Field of Invention This invention relates to combination products comprising low doses of oral anticoagulants, such as warfarin, and low doses of inhibitors of platelet function (e.g., aggregation, adhesion) such as non-steroidal antiinflammatory agents, and preferably

Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications in diseases such as myocardial

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION The present invention relates to variants (mutants) of recombinant protein C and activated protein C, an enzyme that normally has anti-thrombotic, anti-inflammatory, and anti-apoptotic activities. The recombinant activated protein C mutants of the invention have markedly

Protein fusion constructs possessing thrombolytic and anticoagulant properties

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

SEQUENCE LISTING SUBMISSION VIA EFS-WEB A computer readable text file, entitled "102082-5002_SequenceListing.txt," created on or about 23 Sep. 2013, with a file size of about 160 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety. FIELD OF

Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION This invention relates to the treatment of myocardial infarction and more particularly to a therapy for preventing the reocclusion of coronary arteries which often accompanies use of thrombolytic agents in the treatment of myocardial infarction. This invention also relates to

Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION This invention relates to the treatment of myocardial infarction and more particularly to a therapy for preventing the reocclusion of coronary arteries which often accompanies use of thrombolytic agents in the treatment of myocardial infarction. This invention also relates to

DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION This invention relates to the treatment of myocardial infarction and more particularly to a therapy for preventing the reocclusion of coronary arteries which often accompanies use of thrombolytic agents in the treatment of myocardial infarction. This invention also relates to

Method and compositions for inhibiting thrombin-induced coagulation

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION The present invention relates in general to SdrG, a fibrinogen-binding bacterial adhesin, and in particular to the use of SdrG or its binding region as an anti-coagulation agent by virtue of its ability to inhibit thrombin-induced fibrin clot formation by interfering with the

Low molecular weight bicyclic thrombin inhibitors

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION This invention relates to compounds useful for the treatment of thrombotic disorders, and more particularly to novel heterocyclic inhibitors of the enzyme thrombin. BACKGROUND Inordinate thrombus formation on blood vessel walls precipitates acute cardiovascular disease states

Assay for soluble crosslinked fibrin polymers

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

FIELD OF THE INVENTION The present invention relates to a novel assay for use in the diagnosis of patients at risk of thrombosis and in monitoring the effects of treatment of such patients. More particularly, the present invention relates to a novel method for measuring the amount of soluble

Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND OF THE INVENTION It has been more than four decades since the introduction of heparin, warfarin and indandione derivatives for the treatment and preventing of thromboembolic disorders. These drugs remain to be the only effective anticoagulants in use today. They exert their effects by

anticoagulant/infark

PKC activators and anticoagulant in regimen for treating stroke

PKC activators and anticoagulant in regimen for treating stroke

Oral anticoagulant/platelet inhibitor low dose formulation

Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Protein fusion constructs possessing thrombolytic and anticoagulant properties

Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Method and compositions for inhibiting thrombin-induced coagulation

Low molecular weight bicyclic thrombin inhibitors

Assay for soluble crosslinked fibrin polymers

Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals

Database tanaman obat terlengkap yang didukung oleh sains